03.21.25 -- Harnessing The Power Of Cord Blood Tregs With Cellenkos' Dr. Simrit Parmar

This article outlines seven key fundamentals for optimizing IRB submissions and streamlining approvals, keeping their clinical trials on track.

The growing potential of precision medicine is offering an effective way to address challenges that arise across the landscape of neurological care.

The "Australian Advantage" approach offers U.S. biotech firms numerous benefits, including a cash rebate of almost 50%, faster timelines, no IND requirement, and globally accepted data.

Learn about the challenges researchers face when incorporating ophthalmology assessments into clinical trials, and how you can address those obstacles to the benefit of your trial and its participants.

Here, we explore the evolution of a 10-year partnership and extrapolate the principles that create cohesive teams and minimize turnover.

Explore key challenges in accessing and preparing analytics-ready clinical data, how FAIR guiding principles can help maximize the value of clinical trial data, and the impact of innovative analytics.

Learn how bringing clinical trials to any community around the world is not only possible but also increases patient access and reach and improves recruitment and retention.

The patient, product, and value chains for cell and gene therapies are far different than traditional healthcare delivery and requires new and specialized sets of capabilities at hospitals.

Examine the significant CGT advancements in 2024, including new approvals for solid tumors and diabetes treatments, as well as the role of AI and logistical improvements in scaling these therapies.

As cell therapies develop and become more commercialized, manufacturers must adopt a sophisticated supply chain that provides the necessary materials and technologies to support therapeutic development.